US Pharma MarketingEli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost. Eli Lilly gene editing research Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home Pharma Eli Lilly to buy three small vaccine developers The companies are working on shots…
Eli Lilly said Tuesday it would buy three early- and mid-stage vaccine developers, a boost for the field.
The deals — which together could cost up to nearly $4 billion — are the latest acquisitions from Lilly, a company rich with cash from its booming GLP-1 business. In recent months, it’s picked up companies working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each.
The companies being bought are Curevo, LimmaTech Biologics, and Vaccine Company.
Source: STAT News Pharma